Phase I study of putaminal gene transfer with adeno-associated virus serotype 2 [AAV2]-neurturin [NTN] (CERE-120) for Parkinson's disease: Preliminary observations

被引：0
|
作者：
Marks, WJ
Metman, LAV
Starr, PA
Larson, PS
Bakay, RA
Taylor, R
Cahn-Weiner, D
Bartus, RT
Ostrem, JL
机构：
来源：
NEUROLOGY | 2006年 / 66卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A185 / A185
页数：1
相关论文
共 34 条
  • [1] AAV2-neurturin (CERE-120) for Parkinson's disease
    Hickey, Patrick
    Stacy, Mark
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (01) : 137 - 145
  • [2] Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
    Marks, William J., Jr.
    Ostrem, Jill L.
    Verhagen, Leonard
    Starr, Philip A.
    Larson, Paul S.
    Bakay, Roy A. E.
    Taylor, Robin
    Cahn-Weiner, Deborah A.
    Stoessl, A. Jon
    Olanow, C. Warren
    Bartus, Raymond T.
    LANCET NEUROLOGY, 2008, 7 (05): : 400 - 408
  • [3] Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease
    Gasmi, Mehdi
    Herzog, Christopher D.
    Brandon, Eugene P.
    Cunningham, Justine J.
    Ramirez, G. Anthony
    Ketchum, Elias T.
    Bartus, Raymond T.
    MOLECULAR THERAPY, 2007, 15 (01) : 62 - 68
  • [4] Safety and Feasibility of Intranigral and Intraputaminal CERE-120 (AAV2-Neurturin) Administration in Parkinson's Disease
    Siffert, Joao
    Stacy, Mark
    Turner, Dennis
    Tagliati, Michele
    Alterman, Ronald
    Factor, Stewart
    Boulis, Nicholas
    Olanow, C. Warren
    Lang, Anthony
    Lozano, Andres
    Bartus, Raymond
    NEUROLOGY, 2011, 77 (02) : 200 - 200
  • [5] AAV2 - mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson's disease
    Gasmi, Mehdi
    Brandon, Eugene P.
    Herzoga, Christopher D.
    Wilson, Alistair
    Bishop, Kathie M.
    Hofer, Eva K.
    Cunningham, Justine J.
    Printz, Marie A.
    Kordower, Jeffrey H.
    Bartus, Raymond T.
    NEUROBIOLOGY OF DISEASE, 2007, 27 (01) : 67 - 76
  • [6] Bioactivity of AAV2-Neurturin Gene Therapy (CERE-120): Differences Between Parkinson's Disease and Nonhuman Primate Brains
    Bartus, Raymond T.
    Herzog, Christopher D.
    Chu, Yaping
    Wilson, Alistair
    Brown, Lamar
    Siffert, Joao
    Johnson, Eugene M., Jr.
    Olanow, C. Warren
    Mufson, Elliott J.
    Kordower, Jeffrey H.
    MOVEMENT DISORDERS, 2011, 26 (01) : 27 - 36
  • [7] AAV2-neurturin (CERE-120) for Parkinson's disease: 24-month follow-up from the phase I clinical trial
    Marks, W. J., Jr.
    Ostrem, J. L.
    Verhagen, L.
    Starr, P. A.
    Larson, P. S.
    Bakay, R. A. E.
    Olanow, C. W.
    Bartus, R. T.
    MOVEMENT DISORDERS, 2008, 23 (01) : S35 - S36
  • [8] Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
    Kordower, Jeffrey H.
    Herzog, Christopher D.
    Dass, Biplob
    Bakay, Roy A. E.
    Stansell, James, III
    Gasmi, Mehdi
    Bartus, Raymond T.
    ANNALS OF NEUROLOGY, 2006, 60 (06) : 706 - 715
  • [9] Long-term safety of neurotrophic factor gene therapy using AAV2-neurturin (CERE-120) in Parkinson's disease
    Taylor, R.
    Baumann, T.
    Marks, W., Jr.
    Ostrem, J.
    Verhagen, L.
    Stacy, M.
    Deogaonkar, M.
    Vitek, J.
    Watts, R.
    Jankovic, J.
    Cho, C.
    Tagliati, M.
    Stern, M.
    Nutt, J.
    Bartus, R.
    MOVEMENT DISORDERS, 2013, 28 : S40 - S40
  • [10] Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer
    Marks, William J., Jr.
    Baumann, Tiffany L.
    Bartus, Raymond T.
    HUMAN GENE THERAPY, 2016, 27 (07) : 522 - 527
1234